The drug was first approved in March 2006 in Europe to treat early stages of the illness in March 2006 and is available in Germany, Austria, Switzerland, Britain, Ireland, Denmark, Norway, Sweden, Greece and Spain.
The company, which is set to become part of Belgium's UCB SA in a Ђ4.4 billion (US$5.7 billion) deal, has said that sales of the drug could reach as much as Ђ350 million annually, reports AP.
Shares of Schwarz Pharma were up more than half a percent to Ђ106.13 in Frankfurt trading.
The German press came to the conclusion that Russia's Zircon missile sea-launched complex represents a real threat to warships of different countries
On January 15, it was reported that the Russian government began to develop sanctions against several officials at the World Anti-Doping Agency (WADA)